Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Thanks David and all the other people who have commented. Clive it's a good point about the loss of Woodford causing instability but having said that, I'm glad to see the back of him, it's one of the reasons our SP is so low. The wide spread may deter profit takers, but it also deters new investors getting in as they end up with a significant loss just by buying the shares.
13 years have passed since I got in and we are now at 20% of the SP. I completely agree that the science is unbelievable (as is the fact that this hasn't been recognised). There's a danger we'll end up getting bought out by a large pharma for peanuts and all this will have been a waste of time. Most holders would probably take double the current SP but that is actually nothing when you look at the licencing agreements and IP collected over the years.
Michael Hunt has impressed me more with his recent upbeat presentations, but they are still almost completely scientific, which isn't really what you expect from a CFO. I think the market needs some commercial confidence and clear deadlines. The clinical trials never seem to end or get passed Phase 2. Having said all that, this company has got some amazing potential which is why I have stuck it out so long.
Lost count the amount of times someone as posted about this subject. The money and resources available in the LSE one would assume it would be easy to fix this problem as it as been like this for years. IMO it’s deliberately done and definitely not to benefit the Pi.
Prospero. I made a purchase this morning which shows as a sell. The 'sell'or 'buy' label is a guess based on proximity to the bid or offer.
Hi Clivealive
With the many millions in the bank since 2015 they probably hoped to reach some commercial inflections before 2020.
I agree with you and we now know that the board are now being asked to think in terms of deals that build shareholder value near term and not fall into the trap of thinking that the platforms are worth billions so they can sit on their hands and wait for the money to roll in.
Also, I'm really surprised at the poor market response to what is amazingly positive 18 month data against a horrible genetic condition. Maybe we are the only ones that really know about Reneurons possibilities.
Chester.
My observation is that generally anticipated (good) news often fails to move prices whereas "out of the blue" surprises have a much more positive effect. As an example, look at the Rene price spike after the announcement of the Huntington's disease research success using CTX - this came from nowhere. Some good news on exosomes may well change the mindset around the stock, dissuading sellers and attracting new buyers. This is what moves prices upwards.
Prospero17, I think we all agree, it is a very frustrating scenario at present and comments here demonstrate. The stock market is a voting machine and does not necessarily correlate to the actual performance of the business. Its supply and demand hence the broker's difficulty in trying to hold the price by widening the margin to minimise profit-taking, and build the share price on each planned release of good news. The downside to losing Woodford Patient Capital etc. was they protected the long term investor and hence wouldn't sell. We no longer have 32% hold at a 5p/£5 buy-in. Now we are at the mercy of market forces, a catch 22, our shareholder base needs to change so fundamentally we need those who would immediately sell, for a quick profit to move on, as they hold back organic share growth and ability in raising finance. Even with a revised Eddison valuation targeting (though down on previous valuations), a value currently of £3.36, we will continually be knocked-back by supply-demand in shares with to many sellers in it for the short term. Hence why I hope the board is strategising its options, the catch 22 is if to many license agreements are made it will limit the source to funds rather than trade sale in part or full as a means to raise more cash as the share price will continue its roller coaster ride. Far better to be negotiating a major deal with a large listed pharma group who is publically traded and would fund the balance of trials and bring a harder commercial value to the business. This could take the form of a mix of share swap for control (51%) along with a rights issue which they would underwrite. This would be a far better approach to create shareholder value, stabalise the share price and bring new capital to see the business. A win-win situation, allowing shareholders to hold stock in a larger group with a buyout option at a higher price for the balance of their shares for those who participate in the rights issue. I just hope this kind of creative commerciality is being worked on by some members of their board and or advisors. I hope this gets read by board members as they badly need some commercial strategy to raise shareholder value and not just hold onto the science to get them through. Apologies for long post, but wanted to express my views.
I do think it is more a statement of the current life on AIM where various darling like Hurricane, Sirius Minerals et al have lost their owners 50-90% of their investment despite great promise of the sunlit uplands. I am sure that were this stock on Nasdaq with this newsflow it would be worth in the hundreds of millions of $.
The other point is the chart - we have a very interesting technical pattern emerging - you can draw a line from the low of March '20 and thru the low of June '20...and one from the high of Oct '19, May '20 and June '20 which gives us a descending triangle pattern - typically a pretty bearish pattern. Add that to the fact that all 3 major moving averages on the daily chart (20, 50 and 200) all lie between 1.35 and 1.55 and it's pretty obvious we have a major break out coming soon. I've gone way too soon paying £1.38 for a few shares the last week but a clear break of 1.55 and then 1.70 would be a v bullish sign. Sadly, Mr market does not feel that the recent news warrants such a move, which means I probably have to get back in my box!
You and one other have bought shares this morning. All the others are sells. I really don't understand what is going on.
Agreed PC01. The sp went to £3 on less substantial news than this !
Agreed all! So I have gone and bought another 10k at £1.40...the news of the past week and my very patient nature (hahaha) make me feel that someone, one day will see value where we do...
Reneuron has been all about the science because for 5 years they have had a very healthy bank balance and the SP was not critical.
Their focus has now changed as per the recent interview with Micheal Hunt saying that they were requested to park CTX with partners and concentrate on near term commercial opportunities.
We have discussed the state of their finances just recently and they probably have enough cash for 12 months. But it seems they are being asked to focus more on the financial aspects, so I still expect some pivotal news just before or included in the year end report.
This RP data released today increases the odds of a deal being struck with a major player. The further we progress with ever increasing positive data the more expensive it will be for any would be suiter.
Rene's RP platform is now primed and ready for a large partnership deal.
Chester.
well,
great results, think things are fairly settled with this obviously working in my view.
I wish the company though would focus more on investors and in particular doing deals and at least highlighting what will trigger milestones from fosun and how much closer we are etc and what the payments look like.
Still get the feeling that this is just some sort of science project which is painfully slow, with little regard for investors.
Less of the now very tired presentations about the technology and more on commercialisation please.
Agree completely PC, a 4.4% spike on this excellent news is derisory and we still have a spread of 15p (11.11%). People won't take us seriously unless we get out of AIM.
Well I am not sure Chester...the SP seems stuck with a lack of follow through interest. I'm not sure quite what Reneuron has to do to get the SP back above £2...which I think is roughly my b/e! I own plenty and think it remains the most likely of all my AIM 'hopes' (they are not investments are they, really?!) to make a meaningful difference to my life (thru a rising SP) and the lives of the patients it hopes to provide with a long term solution to their underlying health problems. However, it might be evidence as I have previously suggested of an improved cashflow outlook so that we dont get a further significant dilution. I still pin my hat on the fact that directors were buyers way above here and their option strikes are at multiples of the current SP...
On an aside, the market maker 10% bid/offer is a real pi55-take and probably as good a reason as any why we don't see more flows...
What an amazing piece of science.
We must always remember the patients who would more than likely now be blind and the hope that these results will give to others with Retinitus Pigmentosa.
It is excellent to niw have data that proves the long lasting effect of the treatment and that the new photo receptor cells are well established. The maximum dose was 1m stem cells but the next trial has been approved to use 2m, it will be amazing if the doubling of the dose further increases the positive results.
Must say that was a well timed top up by PC01.
Chester.
Very solid results . No sign of the effect wearing off. Increasing the dose to two million stem cells may improve them even further.
Stunning results - I hope to see the sp rise as a consequence.
I had a feeling we'd get something this morning.
Very good trial results so far - all looking positive!